On March 2, 2022 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that its Senior Vice President and Chief Financial Officer, Jonathan Guarino, has been invited to attend the Q1 Virtual Investor Summit (Press release, Soligenix, MAR 2, 2022, View Source [SID1234609390]). The conference will take place March 8-9, 2022, and includes one-on-one meetings and a Company presentation with Q&A at 1:15 P.M. EST on Tuesday, March 8, 2022. The presentation will be available to registered conference attendees via the event platform link. The presentation will be webcast and an archived recording will be made available on the "Investor Events" page of the Company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

If you are unable to attend the conference and would like to schedule a meeting with management, please contact [email protected].

For more information about the Q1 Virtual Investor Summit, please refer to the conference website at View Source